ライフサイエンスコーパス: fungemia

1 aluate patients for ocular manifestations of fungemia.

2 serum or CSF cryptococcal antigen titers and fungemia.

3 sured in serum from patients with persistent fungemia.

4 ations in 1,436 patients with bacteremia and fungemia.

5 d in the urine of a patient with C. albicans fungemia.

6 the intensive care unit when they developed fungemia.

7 ltimately established a sustained, low-level fungemia.

8 ty of the ESP blood culture system to detect fungemia.

9 the incidence of Gram-positive bacteremia or fungemia.

10 atients who were at increased risk of having fungemia.

11 cluding 121 episodes of bacteremia and 12 of fungemia.

12 adult patients with suspected bacteremia or fungemia.

13 btaining blood for culture for bacteremia or fungemia.

14 culture system for detecting bacteremia and fungemia.

15 ative bacteremia, and from 0.6% to 26.1% for fungemia.

16 adult patients with suspected bacteremia or fungemia.

17 osts in patients with documented C. glabrata fungemias.

18 mia (1.6%), gram-positive bacteremia (1.6%), fungemia (1.6%), and documented or suspected aspergillos

19 Of 248 separate episodes of bacteremia or fungemia, 146 were detected by both systems, 56 were det

20 = .16), incidence of secondary bacteremia or fungemia (15% for the ganciclovir group vs 15% for the p

21 croM/mg/dl 3 or more days after the onset of fungemia (18/27 versus 4/24 patients, respectively; P <

22 Of the 36 clinically important episodes of fungemia, 22 were detected by both systems (13 C. albica

23 infection (82.7% vs. 20%, P = 0.00001), and fungemia (29% vs. 8%, P = 0.046) were more likely to rec

24 e mycobacteremia (57/182 vs. 0/64, P<.0001), fungemia (38/182 vs. 2/64, P<.001), or polymicrobial BSI

25 thalmitis was 0.05%-0.4% among patients with fungemia and 0.04% among patients with bacteremia.

26 We present a case of S. cerevisiae fungemia and aortic graft infection in an immunocompeten

27 ul both for the initial diagnosis of Candida fungemia and for prognostic purposes for unselected pati

28 ation between the incidence of bacteremia or fungemia and intravenous lipid (P = 0.95).

29 e major infection (pneumonia, bacteremia, or fungemia) and death; if the true probability of either e

30 s, 100 hospitalized controls without Candida fungemia, and 83 patients from a study of all Candida fu

31 , severe lung pathology, elevated serum IgE, fungemia, and cryptococcal dissemination in the central

32 three predictors (serum antigen titer >1:64, fungemia, and late-onset disease) independently identifi

33 Catheter-associated W. dermatitidis fungemia appears to be distinct from previously describe

34 cT/ALERT aerobic medium for the detection of fungemia as well as bacteremia.

35 id organs from donors with bacteremia and/or fungemia at the time of organ recovery.

36 Only 18 of the 151 clinical episodes of fungemia attributable to yeast were not detected by auto

37 ounts for a significant number of nosocomial fungemias, but in fact, no effective and verified geneti

38 ida glabrata than in patients with cancer or fungemia caused by a DA producer, C. albicans, C. tropic

39 ere less frequent in patients with cancer or fungemia caused by the DA nonproducer Candida glabrata t

40 method combining septicemia, bacteremia, and fungemia codes (P < .001 for linear trend) to a 706% inc

41 ard-dose lipid group developed bacteremia or fungemia compared with 54 in the low-dose lipid group.

42 increased yields in detecting bacteremia and fungemia compared with standard BacT/Alert (STD) bottles

43 and severity of illness, correlated with the fungemia due to a non-albicans species.

44 We report an outbreak investigation of fungemia due to Penicillium species after prolonged floo

45 ted the financial impact of the treatment of fungemias due to Candida glabrata from a hospital perspe

46 ion compared the incidence of bacteremia and fungemia during the first month after the transplant.

47 te lymphoblastic leukemia and Candida krusei fungemia failed therapy with fluconazole and amphoterici

48 ic types of infections, 53% of patients with fungemia had complete responses, and 52% of patients wit

49 ty-two (9.2%) of 238 consulted patients with fungemia had ocular involvement.

50 n days, incidence of secondary bacteremia or fungemia, ICU length of stay, mortality, and ventilator-

51 t fungal isolates involved in 36 episodes of fungemia in 34 patients.

52 ssociated Wangiella (Exophiala) dermatitidis fungemia in a human immunodeficiency virus-infected chil

53 adequate for the detection of bacteremia and fungemia in adults, a recent study found that two blood

54 ory cytokines are associated with persistent fungemia in candidemia patients.

55 tric blood culture tube for the detection of fungemia in children was assessed by a 10-year retrospec

56 ul clinical information for the diagnosis of fungemia in children, with the exception of M. furfur an

57 Alert 3D (BTA3D) for detection of bacteremia/fungemia in four bottle types, SA and FA Plus (aerobic)

58 t Systems, Sparks, Md.) for the detection of fungemia in hospitalized pediatric patients.

59 and 83 patients from a study of all Candida fungemias in Connecticut between October 1998 and Septem

60 Fungemia including polymicrobial infection was due to: C

61 ablishment and maintenance of this sustained fungemia is an important stage of disease progression th

62 Fungemia, mostly due to Candida spp., was rare in cancer

63 fungal blood cultures (n = 215) or suspected fungemia (n = 12).

64 Presentations included fungemia (n = 2), multifocal lymphadenopathy (n = 2), an

65 ion and may result in antibiotic resistance, fungemia, necrotizing enterocolitis (NEC), and mortality

66 Persistent fungemia occurred in 13% of cases.

67 Fungemia occurred in 333 (0.23%; 95% confidence interval

68 s at one hospital developed Candida albicans fungemia or endophthalmitis.

69 5.24), while antifungal prophylaxis prior to fungemia (OR 0.20, 95% CI, .06-.62) and remission of und

70 cryptococcosis who have late-onset disease, fungemia, or serum cryptococcal antigen titer more than

71 P=.023), renal failure at baseline (P=.028), fungemia (P=.006), and disseminated infection (P=.035) a

72 s drawn for 30 (36%), 22 (27%), and 11 (13%) fungemia patients, respectively.

73 Our data suggest that sustained fungemia resulted from a pattern of repeated escape from

74 for Research and Treatment of Cancer (EORTC) fungemia survey, and there are few recent large epidemio

75 , Md.) allowed detection of more episodes of fungemia than did a resin-containing medium with equal v

76 fford more rapid detection of bacteremia and fungemia than is possible with non-instrument-based manu

77 icroorganisms and episodes of bacteremia and fungemia than Standard Anaerobic/F bottles as companion

78 For fungemia, the MFL bottle was as sensitive as the SC-B bo

79 For the subgroup of subjects whose fungemia was diagnosed while they were in the intensive

80 blinded determination of true bacteremia or fungemia was made by two infectious disease specialists.

81 isms from adult patients with bacteremia and fungemia, we compared Plus Anaerobic/F bottles with Stan

82 isms from adult patients with bacteremia and fungemia, we compared the BacT/ALERT FN (FN) anaerobic b

83 ce, clinical characteristics, and outcome of fungemia were analyzed.

84 A total of 54 episodes of fungemia were identified, with 40 detected by both media

85 yptococcal antigen titer more than 1:64, and fungemia were independently associated with an increased

86 Disseminated disease and fungemia were present in 76.8% (86/112) and 90-day morta

87 is the first reported case of S. cerevisiae fungemia where the identity of the pathogen was confirme

88 ay a valuable role in limiting the sustained fungemia, which can lead to meningoencephalitis.

89 od volumes required to detect bacteremia and fungemia with low concentrations of an organism.

90 Although shock developed soon after fungemia with the C. albicans clinical isolate, TNF-alph